FDA accepts PolyPid's D-PLEX100 NDA with priority review
PolyPid Ltd. (NASDAQ: PYPD) announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
